{"id":"W2139430929","doi":"10.1016/s0140-6736(12)61853-4","title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":546,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada); Sunnybrook Health Science Centre; Health Sciences Centre","funders":"ViiV Healthcare","keywords":"Dolutegravir; Raltegravir; Medicine; Emtricitabine; Integrase inhibitor; Abacavir; Lamivudine; Adverse effect; Clinical endpoint; Virology; Internal medicine; Efavirenz; Clinical trial; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003550972,0.002562833,0.006011304,0.0006290652,0.0004844852,0.001538078,0.001471468,0.003450915,0.01005417],"category_scores_gemma":[0.004398592,0.00153099,0.003897299,0.0004973749,0.001767398,0.002469696,0.0006901816,0.004069581,0.001982334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007896199,"about_ca_system_score_gemma":0.0007876899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001198281,"about_ca_topic_score_gemma":0.001935958,"domain_scores_codex":[0.9979469,0.001327154,0.0001361762,0.0002486016,0.0001147237,0.0002263917],"domain_scores_gemma":[0.9973074,0.001263735,0.0005177355,0.0003748191,0.0001131816,0.0004230751],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9909145,0.001449599,0.0001252441,0.0004041995,0.0005836295,0.00001693842,0.00003223799,0.0001186484,0.000962418,0.0000407876,0.000239814,0.005112034],"study_design_scores_gemma":[0.9769542,0.02087272,0.001001766,0.00003297662,0.0004528239,0.00001474114,0.00002112646,0.0001638093,0.0001513957,0.0001382816,0.000178009,0.00001814742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985505,0.006675494,0.0009144419,0.000825538,0.0008975259,0.001370871,0.001485195,0.0001877282,0.002138168],"genre_scores_gemma":[0.9831518,0.003576009,0.001857041,0.00136889,0.000931605,0.001974195,0.0009321195,0.00007994818,0.006128416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01005417,"threshold_uncertainty_score":0.03363454,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03887473312597239,"score_gpt":0.28644908395491,"score_spread":0.2475743508289376,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}